Algert Global LLC Arcus Biosciences, Inc. Transaction History
Algert Global LLC
- $4.04 Billion
- Q1 2025
A detailed history of Algert Global LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Algert Global LLC holds 269,032 shares of RCUS stock, worth $2.55 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
269,032
Previous 180,122
49.36%
Holding current value
$2.55 Million
Previous $2.68 Million
21.25%
% of portfolio
0.05%
Previous 0.06%
Shares
16 transactions
Others Institutions Holding RCUS
# of Institutions
199Shares Held
62.2MCall Options Held
116KPut Options Held
116K-
Black Rock Inc. New York, NY9.76MShares$92.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.69MShares$63.5 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA5.13MShares$48.7 Million0.28% of portfolio
-
State Street Corp Boston, MA3.7MShares$35.1 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.87MShares$27.2 Million0.06% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $685M
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...